Antithrombin-α for the prophylaxis of venous thrombosis in congenital antithrombin deficiency

Fyfe, A. and Tait, R. C. (2009) Antithrombin-α for the prophylaxis of venous thrombosis in congenital antithrombin deficiency. Expert Review of Hematology, 2(5), pp. 499-507. (doi: 10.1586/ehm.09.43) (PMID:21083015)

Full text not currently available from Enlighten.

Abstract

ATryn® is a transgenically produced recombinant antithrombin (AT) concentrate licensed in Europe and the USA for the thromboprophylaxis of hereditary AT-deficient patients undergoing surgical procedures who are at a high risk of venous thromboembolism. It is also licensed, in the USA only, for prevention the of venous thromboembolism in association with delivery and the immediate post-partum period. ATryn is administered as a continuous intravenous infusion, with weight-adjusted loading and maintenance dosing regimens. Recombinant AT has an identical amino acid structure with minor glycosylation differences to endogenous AT. ATryn has a shorter half-life but an equivalent efficacy to that of plasma-derived AT concentrates in the prevention of venous thromboembolism in this rare distinct group with a high thrombotic risk. In addition, this recombinant product should be free from the risk of human viral or prion transmission.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Tait, Dr Robert
Authors: Fyfe, A., and Tait, R. C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Expert Review of Hematology
Publisher:Informa Healthcare
ISSN:1747-4086
ISSN (Online):1747-4094

University Staff: Request a correction | Enlighten Editors: Update this record